文献速递脑血管病癫痫

成人急性缺血性卒中后癫痫预防的比较有效性与安全性

Comparative Effectiveness and Safety of Seizure Prophylaxis Among Adults After Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2022-12-21

本研究利用美国心脏协会「遵循指南」卒中登记与电子健康记录链接数据,纳入2014至2021年≥65岁、新发非重症急性缺血性卒中且近3个月未使用癫痫特异性抗癫痫药物的患者,比较入院7天内启动与不启动癫痫预防对30天死亡率的影响。经标准化后,启动组30天死亡率估计为每1000例251例死亡,未启动组为每1000例120例死亡,风险差为每1000例131例超额死亡(95%CI 65-200)。结论认为启动癫痫预防与更高的30天死亡率相关,不支持其降低卒中后30天死亡率的作用。

要点

  • 启动癫痫预防组30天死亡率估计为每1000例251例死亡,未启动组为每1000例120例死亡。
  • 标准化后风险差为每1000例131例超额死亡(95%CI 65-200),启动组死亡率更高。
  • 研究结论不支持癫痫预防在降低卒中后30天死亡率方面的作用。

核心结论

  • 启动癫痫预防与不启动相比,急性缺血性卒中后30天死亡率风险更高;本研究不支持癫痫预防降低卒中后30天死亡率的作用。

研究设计与样本

  • 利用美国心脏协会「遵循指南」卒中登记与电子健康记录个体链接数据,纳入2014至2021年≥65岁、新发非重症急性缺血性卒中(美国国立卫生研究院卒中严重程度评分≤20)且近3个月未记录使用癫痫特异性抗癫痫药物的患者。
  • 比较入院7天内启动癫痫预防(即癫痫特异性抗癫痫药物)与不启动的效果,使用逆概率加权处理混杂,并进行标准化以考虑相关临床和医疗保健因素。
  • 研究样本包括151例接受抗癫痫药物者和3020例未接受者。

主要发现

  • 粗30天死亡风险在癫痫特异性抗癫痫药物启动组为每1000例219例死亡,未启动组为每1000例120例死亡。
  • 标准化后,启动组估计死亡率为每1000例251例死亡(95%CI 190-307),未启动组为每1000例120例死亡(95%CI 86-144),风险差为每1000例131例超额死亡(95%CI 65-200)。
  • 预设亚组分析中,轻微卒中患者风险差为52(95%CI 11-72),中重度卒中患者风险差为138(95%CI 52-222)。
  • 年龄65至74岁和≥75岁患者风险差分别为86(95%CI 18-118)和157(95%CI 57-219)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older adults occasionally receive seizure prophylaxis in an acute ischemic stroke (AIS) setting, despite safety concerns. There are no trial data available about the net impact of early seizure prophylaxis on post-AIS survival. METHODS: Using a stroke registry (American Heart Association's Get With The Guidelines) individually linked to electronic health records, we examined the effect of initiating seizure prophylaxis (ie, epilepsy-specific antiseizure drugs) within 7 days of an AIS admission versus not initiating in patients ≥65 years admitted for a new, nonsevere AIS (National Institutes of Health Stroke Severity score ≤20) between 2014 and 2021 with no recorded use of epilepsy-specific antiseizure drugs in the previous 3 months. We addressed confounding by using inverse-probability weights. We performed standardization accounting for pertinent clinical and health care factors (eg, National Institutes of Health Stroke Severity scale, prescription counts, seizure-like events). RESULTS: The study sample included 151 patients who received antiseizure drugs and 3020 who did not. The crude 30-day mortality risks were 219 deaths per 1000 patients among epilepsy-specific antiseizure drugs initiators and 120 deaths per 1000 among noninitiators. After standardization, the estimated mortality was 251 (95% CI, 190-307) deaths per 1000 among initiators and 120 (95% CI, 86-144) deaths per 1000 among noninitiators, corresponding to a risk difference of 131 (95% CI, 65-200) excess deaths per 1000 patients. In the prespecified subgroup analyses, the risk difference was 52 (95% CI, 11-72) among patients with minor AIS and 138 (95% CI, 52-222) among moderate-to-severe AIS patients. Similarly, the risk differences were 86 (95% CI, 18-118) and 157 (95% CI, 57-219) among patients aged 65 to 74 years and ≥75 years, respectively. CONCLUSIONS: There was a higher risk of 30-day mortality associated with initiating versus not initiating seizure prophylaxis within 7 days post-AIS. This study does not support the role of seizure prophylaxis in reducing 30-day poststroke mortality.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Moura LMVR, Donahue MA, Yan Z, et al. Comparative Effectiveness and Safety of Seizure Prophylaxis Among Adults After Acute Ischemic Stroke. Stroke. 2022. PMID: 36544249. doi:10.1161/STROKEAHA.122.039946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。